Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

about

Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Item

http://www.wikidata.org/entity/Q26749010

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Ibrutinib: Implications for Us ...... d Chronic Lymphocytic Leukemia

@ast

Ibrutinib: Implications for Us ...... d Chronic Lymphocytic Leukemia

@en

Ibrutinib: Implications for Us ...... d Chronic Lymphocytic Leukemia

@nl

type

Item

label

Ibrutinib: Implications for Us ...... d Chronic Lymphocytic Leukemia

@ast

Ibrutinib: Implications for Us ...... d Chronic Lymphocytic Leukemia

@en

Ibrutinib: Implications for Us ...... d Chronic Lymphocytic Leukemia

@nl

prefLabel

Ibrutinib: Implications for Us ...... d Chronic Lymphocytic Leukemia

@ast

Ibrutinib: Implications for Us ...... d Chronic Lymphocytic Leukemia

@en

Ibrutinib: Implications for Us ...... d Chronic Lymphocytic Leukemia

@nl

P1476

Ibrutinib: Implications for Us ...... d Chronic Lymphocytic Leukemia

@en

P2093

Gretchen Anne McNally

http://www.w3.org/2001/XMLSchema#string

Jennifer M Long

http://www.w3.org/2001/XMLSchema#string

Lynne R Brophy

http://www.w3.org/2001/XMLSchema#string

Maria R Badillo

http://www.w3.org/2001/XMLSchema#string

P2860

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.

Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment.

The microenvironment in mature B-cell malignancies: a target for new treatment strategies

P304

420-31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.6004/JADPRO.2015.6.5.3

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27069735

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte

P932

4803460

http://www.w3.org/2001/XMLSchema#string